Brensocatib: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 404 patientsc19early.org

Brensocatib for COVID-19

Serious outcome risk
Brensocatib
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−41%
Mortality (1)−41%
RCTs (1)−41%
Late (1)−41%
00.511.5+
← Brensocatib
reduces riskIncreased
risk →
c19early.org
October 2026

Brensocatib COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.88death29/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →
c19early.org
October 2026

Brensocatib COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.8829/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →
c19early.org
October 2026

Brensocatib COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.88death29/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →
c19early.org
October 2026

Brensocatib COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.88death29/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →
c19early.org
October 2026

Brensocatib COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.8829/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →
c19early.org
October 2026

Brensocatib COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Keir (DB RCT)−41%1.41 · 1.06–1.88death29/19023/214STOP-COVID19
Late treatment−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.19
All studies−41%1.41 · 0.85–2.3529/19023/21441% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+
Rotate screen for more detailsIncrease width for more details
← Brensocatib
reduces riskBrensocatib
increases risk →